{"source": "The New York Times", "lead_paragraph": "Samuel D. Waksal is not letting his past stand in the way of his future. Mr. Waksal, the former chief executive of the biotechnology company ImClone Systems, spent five years in federal prison after admitting to insider stock trading and other crimes.", "keywords": [{"rank": "1", "name": "type_of_material", "value": "News"}], "multimedia": [], "snippet": "Not yet two years after serving time for insider trading, Samuel Waksal is again making deals. He says his new venture, Kadmon Pharmaceuticals, will be \"a fully integrated biopharmaceutical company from the get-go,\" replete with everything, including...", "print_page": null, "blog": [], "headline": {"kicker": "DealBook", "main": "ImClone Ex-Chief Embarks on New Biotech Venture"}, "_id": "4fd39d248eb7c8105d8de153", "web_url": "http://dealbook.nytimes.com/2010/11/01/imclone-ex-chief-embarks-on-new-biotech-venture/", "slideshow_credits": null, "byline": {"person": [{"organization": "", "rank": 1, "role": "reported"}], "original": "By DEALBOOK"}, "news_desk": null, "word_count": 147, "document_type": "blogpost", "type_of_material": "Blog", "abstract": "Not yet two years after serving time for insider trading, Samuel Waksal is again making deals. He says his new venture, Kadmon Pharmaceuticals, will be \"a fully integrated biopharmaceutical company from the get-go,\" replete with everything, including its own research and products on the market or in clinical trials that it acquires from others.", "pub_date": "2010-11-01T02:37:18Z", "subsection_name": null, "section_name": "Business Day"}